The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Biology Consortium, 2019Biochemical and Structural Characterization of LRRK2-specific Nanobodies
Study Rationale:
Malfunctioning of the protein leucine-rich repeat kinase 2 (LRRK2) is a common genetic cause of Parkinson’s disease (PD). LRRK2 is a very large and complex protein, and insight into t... -
Research Grant, 2019Functional Evaluation of Alpha-synuclein Dosage Effects in CRISPR‐edited SNCA Model
Promising Outcomes of Original Grant:
The goal of our original grant was to develop a patient-derived stem cell model from skin cells with different expression levels of protein alpha-synuclein, which... -
GBA Biology and Therapies, 2019Expression of GCase throughout Brain Vasculature for Degradation of Alpha-synuclein Aggregates
Study Rationale:
Alpha-synuclein toxicity is caused by progressive accumulation of this protein in cells. Alpha-synuclein protein aggregation is helped along by impaired lysosomes... -
Research Grant, 2019Assessment and Monitoring of Neuromotor Function through Advanced Dynamic Pose Estimation
Study Rationale:
Parkinson’s disease (PD) begins well before movement symptoms appear, and many people have a long journey to diagnosis. No objective test for Parkinson’s exists. If we are able to... -
Alpha-synculein Biology and Therapies, 2018Ordering the Earliest Neuronal Response Events to Native Alpha-synuclein Exposure
Study Rationale:
The protein alpha-synuclein forms aggregates in the brains of people with Parkinson’s. Here, we will not look at the end stage of protein aggregation and cell death, which has been... -
Alpha-synculein Biology and Therapies, 2018Structure and Function of Alpha-synuclein at the Pre-synapse
Study Rationale:
Current therapeutic strategies against synucleinopathies aim to either stabilize a native form of alpha-synuclein or to reduce its levels in patients. However, the normal...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.